Alogliptin does not decrease the risk of heart attack and stroke .
Alogliptin ( trade name Nesina and Vipidia ) is an oral anti-diabetic drug in the DPP - 4 inhibitor ( gliptin ) class .
Vipidia does not decrease the risk of heart attack and stroke .
Alogliptin ( trade name Nesina and Vipidia ) is an oral anti-diabetic drug in the DPP - 4 inhibitor ( gliptin ) class .